Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053246 · ClinicalTrials.gov registry record · Phase 4
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
A Phase 4 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT02053246 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 11 participants.
The verdict
NCT02053246, a Phase 4 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of pulmonary hypertension (PH). Despite the severity of this disease, no established treatments exist for this class of PH. Nebivolol is a drug used in high blood pressure and heart failure, but not used in patients with PH. Due to some additional properties it possesses, the investigators believe nebivolol will improve disease severity in patients with PH associated with HFpEF. The hypothesis of this research study is that nebivolol improves PH severity in patients with HFpEF, as measured by hemodynamic and clinical parameters.
Interventions
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-01 |
| Est. Completion | 2021-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02053246
The ClinicalTrials.gov registry entry for NCT02053246 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol is the first listed.
NCT02053246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02053246 about?
NCT02053246 is a clinical study titled "Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure". Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of pulmonary hypertension (PH). Despite the severity of this disease, no established treatments exist for this class of PH. Nebivolol is a drug used in high blood pressure and heart failure, but not used in patients...
What is the current status of trial NCT02053246?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2014-01. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02053246?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT02053246?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.